

Transparency Reporting at Kyowa Kirin Methodological Note for 2021 data

1. Introduction

Kyowa Kirin Pharma s.r.o. is committed to supporting healthcare and the development of patient care across Czechia. We are pleased to do this through providing funds to Healthcare Organisations (HCOs) or Healthcare Practitioners (HCPs) and through engaging them for services that contribute to the improvement of patient care. In accordance with AIFP Disclosure Code, Kyowa Kirin Pharma s.r.o. publishes details about transfers of value to these individuals and organisations annually.

Each Kyowa Kirin affiliate in Europe is accountable for capturing and validating data in their nation and we make one disclosure per market. This disclosure covers transfers of value between 1st January 2021 to 31st December 2021 to HCPs and HCOs which are registered in the Czech Republic.

2. Scope of disclosure

This disclosure includes the following transfers of value:

EFPIA Category	EFPIA sub-category	Example activities (not exhaustive)
Donations and grants	N/A	<ul style="list-style-type: none"> • Donations to HCOs • Educational grants • Investigation Sponsored Studies
Contribution to cost of events	Sponsorship agreements	<ul style="list-style-type: none"> • Sponsorship of congresses organised by HCOs or third-parties on their behalf
	Registration fees	<ul style="list-style-type: none"> • Funding of HCPs to attend congresses
	Travel and accommodation	<ul style="list-style-type: none"> • HCP's travel and accommodation costs for attending congresses
Fees for service	Fees	Fees for:

		<ul style="list-style-type: none"> • Chairing or attending Advisory Boards • Speaking engagements • Medical writing
	Related expenses	Travel and accommodation expenses relating to the activities above.
Research and Development	N/A	Activities relating to: <ul style="list-style-type: none"> • planning or conduct of clinical studies • clinical trials • non-interventional studies that are prospective in nature • clinical investigator meetings

If activities relate to retrospective non-interventional studies then they are included in Fees for Service, rather than Research and Development.

This disclosure excludes the following transfers of value:

- Hospitality cost (e.g. meals and drinks) unless these are an integral and inseparable part of contributions to the cost of events
- Informational and educational materials and items of medical utility, in line with article 9 of the EFPIA HCP/HCO Disclosure Code
- Logistical costs related to KKI-organised meetings (e.g. room hire)

As the AIFP Disclosure Code only relates to transfers of value to HCPs and HCOs, this disclosure does not include:

- Donations to non-HCOs
- Support provided to Patient Organisations. This is disclosed in a separate report.

Some HCPs continue to provide advice to the healthcare community after they have retired. Generally KKI include such HCPs in the applicable regulation's definition of an HCP, however this depends on their role and ability to prescribe and influence.

3. Date of Transfers of Value

The date of the transfers of value included in this disclosure is based on date of payment (where the transfer of value is a payment).

If the transfer of value is a benefit in kind, it is based on the date when the contract was concluded.

4. Direct and Indirect Transfers of Value

For direct transfers of value, the recipient is considered to be the person or entity holding the bank account receiving the money.

Kyowa Kirin Pharma s.r.o. also provides indirect transfers of value.

In the case of payments that are made through Clinical Research Organisations, these are included under Research and Development and reported in the aggregate.

Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCO.

Where third parties are appointed by KKI to make travel and accommodation arrangements for HCPs, the transfers of value are reported against the HCP who received the benefit.

5. Cross-border activities

KKI makes best efforts to capture and report all transfers of value to HCPs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's principal practice or the HCO's country of registration.

6. Consent

In the Czech Republic, HCOs are reported without the need for consent as they are legal entities.



HCP's consent is collected at the time of contracting. If consent is not provided, the transfer of value that they have received is included in the aggregate amount. If no response is received a "no" response is assumed and the data is also reported in the aggregate.

7. Disclosure

Our report of transfers of value in 2021 is published on [AIFP website](#) in Czech.

The currency used for disclosure is CZK.

In the case that payments are made in a currency other than CZK the payment amount is converted to CZK using the daily exchange rate between the two currencies on the day of payment.

All Transfers of Value include VAT where applicable.

Any questions regarding this disclosure should be directed to:

Kyowa Kirin Pharma s.r.o.
Senovážné náměstí 992/8
Nové Město, 110 00 Praha 1